Hypertrophic Cardiomyopathy Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Machine learning ‐driven diagnostic signature provides new insights in clinical management of hypertrophic cardiomyopathy
ConclusionsOur study revealed a number of hub genes and novel pathways to provide potential targets for the treatment of HCM. A stable model was developed, providing an efficient tool for the diagnosis of HCM. (Source: ESC Heart Failure)
Source: ESC Heart Failure - April 17, 2024 Category: Cardiology Authors: Shutong Liu, Peiyu Yuan, Youyang Zheng, Chunguang Guo, Yuqing Ren, Siyuan Weng, Yuyuan Zhang, Long Liu, Zhe Xing, Libo Wang, Xinwei Han Tags: Original Article Source Type: research

Prevalence and Predictors of Readmissions Among Patients with Hypertrophic Cardiomyopathy and Atrial Fibrillation/Flutter
Atrial fibrillation/flutter (AF) is the most common dysrhythmia in patients with hypertrophic cardiomyopathy (HCM). Unexplained left ventricular hypertrophy and left ventricular outflow tract (LVOT) obstruction are integral components of HCM pathology which can cause increased left atrial pressure and atrial myopathy contributing to the substrate for AF. Our aim was to determine the impact of AF on hospital readmissions in patients with HCM. We conducted a retrospective analysis using the 2015 - 2019 Nationwide Readmission Database to analyze the effect of AF on 30-day readmission and causes of 30-day readmission in patien...
Source: The American Journal of Cardiology - April 16, 2024 Category: Cardiology Authors: Muhammad Usman Almani, Khawaja Muhammad Talha, Laibah Arhsad Khan, Ishaque Hameed, Zain Ul Abideen Asad, Marat Fudim, Richard Krasuski, Muhammad Shahzeb Khan Source Type: research

Incremental value of diastolic wall strain in predicting heart failure events in patients with atrial fibrillation
This study aims to assess DWS as a predictor of HF in AF patients with preserved ejection fraction. We analysed a prospective database of AF patients undergoing transthoracic echocardiography. AF patients with reduced left ventricular ejection fraction (< 50%), posterior wall motion abnormality, hypertrophic cardiomyopathy, valvular heart disease, pericardial disease, congenital heart disease, or history of pacemaker/implantable cardioverter-defibrillator implantation or cardiac surgery were excluded. The study followed patients until HF developme nt, death, or last visit. Follow-up for patients who underwent cathete...
Source: Heart and Vessels - April 16, 2024 Category: Cardiology Source Type: research

Prevalence and Predictors of Readmissions in Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation/Flutter
Atrial fibrillation/flutter (AF) is the most common dysrhythmia in patients with hypertrophic cardiomyopathy (HCM). Unexplained left ventricular hypertrophy and left ventricular outflow tract obstruction are integral components of HCM pathology which can cause increased left atrial pressure and atrial myopathy contributing to the substrate for AF. We aimed to determine the impact of AF on hospital readmissions in patients with HCM. We conducted a retrospective analysis using the 2015 to 2019 Nationwide Readmission Database to analyze the effect of AF on 30-day readmission and causes of 30-day readmission in patients with H...
Source: The American Journal of Cardiology - April 16, 2024 Category: Cardiology Authors: Muhammad Usman Almani, Khawaja Muhammad Talha, Laibah Arhsad Khan, Ishaque Hameed, Zain Ul Abideen Asad, Marat Fudim, Richard Krasuski, Muhammad Shahzeb Khan Source Type: research

The role of cardiac magnetic resonance in sports cardiology: results from a large cohort of athletes
ConclusionCMR is more efficient in identifying a pathologic cardiac substrate in athletes in case of VAs (i.e., polymorphic beats), abnormal ECG repolarisation (negative T-waves in inferolateral leads), and borderline echocardiographic findings (LV hypertrophy, mildly depressed LV function). On the other hand, CMR is associated with a large proportion of negative results. Therefore, a careful clinical selection is needed to indicate CMR in athletes appropriately.Graphical AbstractClinical indications for CMR and positive CMR findings.The left panel shows clinical indications for CMR in our athletic cohort and the percentag...
Source: Clinical Research in Cardiology - April 15, 2024 Category: Cardiology Source Type: research

Carnitine palmitoyltransferase II (CPT II) deficiency responsible for refractory cardiac arrhythmias, acute multiorgan failure and early fatal outcome
ConclusionsCPTII deficiency may be suspected in newborns showing cardiac arrhythmias, associated or not with hypertrophic cardiomyopathy, polycystic kidneys, brain malformations, hepatomegaly. Its diagnosis should be even more suspected and investigated in cases of increased plasmatic levels of creatine phosphokinase and acylcarnitines in addition to kidney, heart and liver dysfunctions, as occurred in the present patient. Accurate family history, extended metabolic screening, and multidisciplinary approach are necessary for diagnosis and adequate management of affected subjects. Next generation sequencing (NGS) techniques...
Source: Italian Journal of Pediatrics - April 14, 2024 Category: Pediatrics Source Type: research

Incidence of Newly Recognized Atrial Fibrillation in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Mavacamten
Mavacamten is a cardiac myosin inhibitor that has been shown to reduce left ventricular outflow tract obstruction in obstructive hypertrophic cardiomyopathy (oHCM).1 In late-stage clinical trials, atrial fibrillation (AF) represented an adverse event in 2-4 % of the patients randomized to mavacamten.1,2 However, the effect of mavacamten on the frequency and management of new/recurrent AF episodes in oHCM receiving mavacamten following its Food and Drug Administration (FDA) approval remains only partially explored. (Source: Heart Rhythm)
Source: Heart Rhythm - April 13, 2024 Category: Cardiology Authors: Matteo Castrichini, Said Alsidawi, Jeffrey B. Geske, Darrell B. Newman, Adelaide M. Arruda-Olson, J. Martijn Bos, Steve R. Ommen, Konstantinos C. Siontis, Michael J. Ackerman, John R. Giudicessi Source Type: research

Transapical intramyocardial septal microwave ablation in treatment of hypertrophic obstructive cardiomyopathy: 12-month outcomes of a swine model
To date, the extended Morrow procedure is considered the gold standard treatment for patients with obstructive hypertrophic cardiomyopathy who experience severe symptoms and are unresponsive to medication trea... (Source: Journal of Cardiothoracic Surgery)
Source: Journal of Cardiothoracic Surgery - April 13, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Mi Zhou, Zhaolong Li, Yun Liu, Yuehua Fang, Le Qin, Wenjie Yang, Fuhua Yan and Qiang Zhao Tags: Research Source Type: research

Novel Therapies for the Treatment of Cardiovascular Disease
Over the last decade, randomized clinical trials of several pharmacologic agents have demonstrated a reduction in cardiovascular mortality and other important secondary outcomes. Angiotensin-Neprilysin Inhibitors and Sodium-Glucose Co-transporter 2 inhibitors have now become pillars in the treatment of heart failure. Ivabradine is a negative chronotropic agent used as an adjunctive therapy in patients with heart failure. Two new hypertension therapies, zilebresiran and aprocitentan, are currently in investigational stages. Finally, mavacamten has emerged as a pharmacologic treatment for hypertrophic obstructive cardiomyopa...
Source: Medical Clinics of North America - April 12, 2024 Category: Primary Care Authors: Abdul Aziz A. Asbeutah, Zachary D. Goldberger Source Type: research

Atrial Fibrillation and Clonal Hematopoiesis in TET2 and ASXL1
CONCLUSIONS AND RELEVANCE: Large TET2 and ASXL1, but not DNMT3A, CHIP was associated with higher IL-6 level, indices of cardiac remodeling, and increased risk for AF. Future research is needed to elaborate on the mechanisms driving the associations and to investigate potential interventions to reduce the risk.PMID:38598228 | DOI:10.1001/jamacardio.2024.0459 (Source: Atherosclerosis)
Source: Atherosclerosis - April 10, 2024 Category: Cardiology Authors: Seyedmohammad Saadatagah Mohammadreza Naderian Mesbah Uddin Ozan Dikilitas Abhishek Niroula Art Schuermans Elizabeth Selvin Ron C Hoogeveen Kunihiro Matsushita Vijay Nambi Bing Yu Lin Yee Chen Alexander G Bick Benjamin L Ebert Michael C Honigberg Na Li Am Source Type: research

Atrial Fibrillation and Clonal Hematopoiesis in TET2 and ASXL1
CONCLUSIONS AND RELEVANCE: Large TET2 and ASXL1, but not DNMT3A, CHIP was associated with higher IL-6 level, indices of cardiac remodeling, and increased risk for AF. Future research is needed to elaborate on the mechanisms driving the associations and to investigate potential interventions to reduce the risk.PMID:38598228 | PMC:PMC11007653 | DOI:10.1001/jamacardio.2024.0459 (Source: Atherosclerosis)
Source: Atherosclerosis - April 10, 2024 Category: Cardiology Authors: Seyedmohammad Saadatagah Mohammadreza Naderian Mesbah Uddin Ozan Dikilitas Abhishek Niroula Art Schuermans Elizabeth Selvin Ron C Hoogeveen Kunihiro Matsushita Vijay Nambi Bing Yu Lin Yee Chen Alexander G Bick Benjamin L Ebert Michael C Honigberg Na Li Am Source Type: research

Focal ischemic myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy
In patients with hypertrophic cardiomyopathy (HCM), ischemic myocardial fibrosis assessed by late gadolinium enhancement (I-LGE) using cardiovascular magnetic resonance (CMR) have been reported. However, the c... (Source: BMC Cardiovascular Disorders)
Source: BMC Cardiovascular Disorders - April 9, 2024 Category: Cardiology Authors: Yang Zhi, Fu-dan Gui, Meng Xue, Yi-tian Long, Wen Miao, You Yi, Liang-chao Gao, Fu Bing and Shu-yue Pan Tags: Research Source Type: research

Mavacamten: A Review of a Novel Therapeutic Approach for Hypertrophic Cardiomyopathy
Cardiovasc Hematol Agents Med Chem. 2024 Apr 5. doi: 10.2174/0118715257283752240325082733. Online ahead of print.ABSTRACTHypertrophic Cardiomyopathy (HCM) is a heart disease that can cause left ventricular hypertrophy, arrhythmias, heart failure, and sudden cardiac death. Currently, pharmacological treatment is limited and ineffective. Mavacamten (CamzyosTM) is a cardiac myosin inhibitor developed as a therapeutic option to reduce myocardial contractility and restoration of myocardial function. The Food and Drug Administration (FDA) approved the use of Mavacamten in 2022 for HCM symptoms. Clinical studies have proven that ...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - April 8, 2024 Category: Cardiology Authors: Ayesha Abdul Qadir Memon Areeba Shamim Sanoober Mirza Muhammad Osama Iyad Naeem Muhammad Calvin R Wei Source Type: research